m6A甲基化修饰在消化系统肿瘤中的研究进展

doi:10.3760/cma.j.cn371439-20210906-00136

摘要/Abstract

摘要：

N⁶-甲基腺嘌呤(m⁶A)甲基化修饰即RNA腺嘌呤第6位氮原子的甲基化,这一动态过程由编码器、消码器、读码器共同调控。越来越多研究表明m⁶A甲基化修饰影响消化系统肿瘤发生发展的多个环节如增殖、侵袭、转移、耐药等。对m⁶A甲基化修饰在消化系统肿瘤中所扮演角色的深入了解将有助于新型精准诊疗策略的建立进而改善患者的总体预后。

关键词: 甲基化, 消化系统肿瘤, 生物标记物, N⁶-甲基腺嘌呤

Abstract:

N⁶-methyladenosine (m⁶A) methylation modification is defined as the methylation at the N⁶ position of adenosine. This dynamic process is regulated by writer, eraser and reader. Accumulating evidence indicates that m⁶A methylation modification is involved in the initiation and development of various digestive system neoplasms including proliferation, invasion, metastasis and chemoresistance. A further understanding about the role of m⁶A methylation modification in digestive system neoplasms will benefit the development of a novel precise diagnostic and therapeutic strategy and finally improve the overall prognosis of patients.

Key words: Methylation, Digestive system neoplasms, Biomarker, N⁶-methyladenosine

刘培培, 杨梦雪, 严雪冰. m⁶A甲基化修饰在消化系统肿瘤中的研究进展[J]. 国际肿瘤学杂志, 2021, 48(11): 688-692.

Liu Peipei, Yang Mengxue, Yan Xuebing. Research advances of m⁶A methylation modification in digestive system neoplasms[J]. Journal of International Oncology, 2021, 48(11): 688-692.

参考文献 42

[1]	Darwiche N. Epigenetic mechanisms and the hallmarks of cancer: an intimate affair[J]. Am J Cancer Res, 2020, 10(7):1954-1978. pmid: 32774995
[2]	Chen M, Wong CM. The emerging roles of N⁶-methyladenosine (m⁶A) deregulation in liver carcinogenesis[J]. Mol Cancer, 2020, 19(1):44. DOI: 10.1186/s12943-020-01172-y. doi: 10.1186/s12943-020-01172-y
[3]	Wang Q, Chen C, Ding Q, et al. METTL3-mediated m⁶A modification of HDGF mRNA promotes gastric cancer progression and has prognostic significance[J]. Gut, 2020, 69(7):1193-1205. DOI: 10.1136/gutjnl-2019-319639. doi: 10.1136/gutjnl-2019-319639
[4]	Tian J, Zhu Y, Rao M, et al. N⁶-methyladenosine mRNA methy-lation of PIK3CB regulates AKT signalling to promote PTEN-deficient pancreatic cancer progression[J]. Gut, 2020, 69(12):2180-2192. DOI: 10.1136/gutjnl-2019-320179. doi: 10.1136/gutjnl-2019-320179
[5]	Song P, Feng L, Li J, et al. β-catenin represses miR455-3p to stimulate m⁶A modification of HSF1 mRNA and promote its translation in colorectal cancer[J]. Mol Cancer, 2020, 19(1):129. DOI: 10.1186/s12943-020-01244-z. doi: 10.1186/s12943-020-01244-z
[6]	Wang T, Kong S, Tao M, et al. The potential role of RNA N⁶-methyladenosine in cancer progression[J]. Mol Cancer, 2020, 19(1):88. DOI: 10.1186/s12943-020-01204-7. doi: 10.1186/s12943-020-01204-7
[7]	Wang X, Lu Z, Gomez A, et al. N⁶-methyladenosine-dependent regulation of messenger RNA stability[J]. Nature, 2014, 505(7481):117-120. DOI: 10.1038/nature12730. doi: 10.1038/nature12730
[8]	Zhu ZM, Huo FC, Pei DS. Function and evolution of RNA N⁶-methyladenosine modification[J]. Int J Biol Sci, 2020, 16(11):1929-1940. DOI: 10.7150/ijbs.45231. doi: 10.7150/ijbs.45231
[9]	Ji P, Wang X, Xie N, et al. N⁶-methyladenosine in RNA and DNA: an epitranscriptomic and epigenetic player implicated in determination of stem cell fate[J]. Stem Cells Int, 2018, 2018:3256524. DOI: 10.1155/2018/3256524.
[10]	Lu J, Qian J, Yin S, et al. Mechanisms of RNA N⁶-methyladenosine in hepatocellular carcinoma: from the perspectives of etiology[J]. Front Oncol, 2020, 10:1105. DOI: 10.3389/fonc.2020.01105. doi: 10.3389/fonc.2020.01105
[11]	Imam H, Khan M, Gokhale NS, et al. N⁶-methyladenosine modification of hepatitis B virus RNA differentially regulates the viral life cycle[J]. Proc Natl Acad Sci U S A, 2018, 115(35):8829-8834. DOI: 10.1073/pnas.1808319115. doi: 10.1073/pnas.1808319115
[12]	Fang Q, Chen H. The significance of m⁶A RNA methylation regulators in predicting the prognosis and clinical course of HBV-related hepatocellular carcinoma[J]. Mol Med, 2020, 26(1):60. DOI: 10.1186/s10020-020-00185-z. doi: 10.1186/s10020-020-00185-z
[13]	Chen M, Wei L, Law CT, et al. RNA N⁶-methyladenosine methyltransferase-like 3 promotes liver cancer progression through YTHDF2-dependent posttranscriptional silencing of SOCS2[J]. Hepato-logy, 2018, 67(6):2254-2270. DOI: 10.1002/hep.29683.
[14]	Zhang C, Huang S, Zhuang H, et al. YTHDF2 promotes the liver cancer stem cell phenotype and cancer metastasis by regulating OCT4 expression via m⁶A RNA methylation[J]. Oncogene, 2020, 39(23):4507-4518. DOI: 10.1038/s41388-020-1303-7. doi: 10.1038/s41388-020-1303-7
[15]	Cheng X, Li M, Rao X, et al. KIAA1429 regulates the migration and invasion of hepatocellular carcinoma by altering m⁶A modification of ID2 mRNA[J]. Onco Targets Ther, 2019, 12:3421-3428. DOI: 10.2147/ott.s180954. doi: 10.2147/OTT
[16]	Chen Y, Peng C, Chen J, et al. WTAP facilitates progression of hepatocellular carcinoma via m⁶A-HuR-dependent epigenetic silencing of ETS1[J]. Mol Cancer, 2019, 18(1):127. DOI: 10.1186/s12943-019-1053-8. doi: 10.1186/s12943-019-1053-8
[17]	Zuo X, Chen Z, Gao W, et al. M⁶A-mediated upregulation of LINC00958 increases lipogenesis and acts as a nanotherapeutic target in hepatocellular carcinoma[J]. Hematol Oncol, 2020, 13(1):5. DOI: 10.1186/s13045-019-0839-x.
[18]	Zhao M, Jia M, Xiang Y, et al. METTL3 promotes the progression of hepatocellular carcinoma through m⁶A-mediated up-regulation of microRNA-873-5p[J]. Am J Physiol Gastrointest Liver Physiol, 2020, 319(5):G636. DOI: 10.1152/ajpgi.00161.2020. doi: 10.1152/ajpgi.00161.2020
[19]	Lin Y, Wei X, Jian Z, et al. METTL3 expression is associated with glycolysis metabolism and sensitivity to glycolytic stress in hepatocellular carcinoma[J]. Cancer Med, 2020, 9(8):2859-2867. DOI: 10.1002/cam4.2918. doi: 10.1002/cam4.v9.8
[20]	Zhou Y, Yin Z, Hou B, et al. Expression profiles and prognostic significance of RNA N⁶-methyladenosine-related genes in patients with hepatocellular carcinoma: evidence from independent datasets[J]. Cancer Manag Res, 2019, 11:3921-3931. DOI: 10.2147/CMAR.S191565. doi: 10.2147/CMAR.S191565 pmid: 31118805
[21]	Wu X, Zhang X, Tao L, et al. Prognostic value of an m⁶A RNA methylation regulator-based signature in patients with hepatocellular carcinoma[J]. Biomed Res Int, 2020, 2020: 2053902. DOI: 10.1155/2020/2053902.
[22]	Zhang J, Bai R, Li M, et al. Excessive miR-25-3p maturation via N⁶-methyladenosine stimulated by cigarette smoke promotes pancreatic cancer progression[J]. Nat Commun, 2019, 10(1):1858. DOI: 10.1038/s41467-019-09712-x. doi: 10.1038/s41467-019-09712-x
[23]	Wang M, Liu J, Zhao Y, et al. Upregulation of METTL14 mediates the elevation of PERP mRNA N⁶ adenosine methylation promoting the growth and metastasis of pancreatic cancer[J]. Mol Cancer, 2020, 19(1):130. DOI: 10.1186/s12943-020-01249-8. doi: 10.1186/s12943-020-01249-8 pmid: 32843065
[24]	Guo X, Li K, Jiang W, et al. RNA demethylase ALKBH5 prevents pancreatic cancer progression by posttranscriptional activation of PER1 in an m⁶A-YTHDF2-dependent manner[J]. Mol Cancer, 2020, 19(1):91. DOI: 10.1186/s12943-020-01158-w. doi: 10.1186/s12943-020-01158-w
[25]	Hou J, Wang Z, Li H, et al. Gene signature and identification of clinical trait-related m⁶A regulators in pancreatic cancer[J]. Front Genet, 2020, 11:522. DOI: 10.3389/fgene.2020.00522. doi: 10.3389/fgene.2020.00522
[26]	Geng Y, Guan R, Hong W, et al. Identification of m⁶A-related genes and m⁶A RNA methylation regulators in pancreatic cancer and their association with survival[J]. Ann Transl Med, 2020, 8(6):387. DOI: 10.21037/atm.2020.03.98. doi: 10.21037/atm.2020.03.98 pmid: 32355831
[27]	Taketo K, Konno M, Asai A, et al. The epitranscriptome m⁶A writer METTL3 promotes chemo- and radioresistance in pancreatic cancer cells[J]. Int J Oncol, 2018, 52(2):621-629. DOI: 10.3892/ijo.2017.4219.
[28]	Wang Q, Geng W, Guo H, et al. Emerging role of RNA methyltransferase METTL3 in gastrointestinal cancer[J]. Hematol Oncol, 2020, 13(1):57. DOI: 10.1186/s13045-020-00895-1.
[29]	Yang DD, Chen ZH, Yu K, et al. METTL3 promotes the progression of gastric cancer via targeting the MYC pathway[J]. Front Oncol, 2020, 10:115. DOI: 10.3389/fonc.2020.00115. doi: 10.3389/fonc.2020.00115
[30]	Yan J, Huang X, Zhang X, et al. LncRNA LINC00470 promotes the degradation of PTEN mRNA to facilitate malignant behavior in gastric cancer cells[J]. Biochem Biophys Res Commun, 2020, 521(4):887-893. DOI: 10.1016/j.bbrc.2019.11.016. doi: 10.1016/j.bbrc.2019.11.016
[31]	Yue B, Song C, Yang L, et al. METTL3-mediated N⁶-methyladenosine modification is critical for epithelial-mesenchymal transition and metastasis of gastric cancer[J]. Mol Cancer, 2019, 18(1):142. DOI: 10.1186/s12943-019-1065-4. doi: 10.1186/s12943-019-1065-4
[32]	Xie JW, Huang XB, Chen QY, et al. m⁶A modification-mediated BATF2 acts as a tumor suppressor in gastric cancer through inhibition of ERK signaling[J]. Mol Cancer, 2020, 19(1):114. DOI: 10.1186/s12943-020-01223-4. doi: 10.1186/s12943-020-01223-4
[33]	Pi J, Wang W, Ji M, et al. YTHDF1 promotes gastric carcinogenesis by controlling translation of FZD7[J]. Cancer Res, 2020, 11: canres.0066.2020. DOI: 10.1158/0008-5472.can-20-0066. DOI: 10.1158/0008-5472.can-20-0066.
[34]	Li Y, Zheng D, Wang F, et al. Expression of demethylase genes, FTO and ALKBH1, is associated with prognosis of gastric cancer[J]. Dig Dis Sci, 2019, 64(6):1503-1513. DOI: 10.1007/s10620-018-5452-2. doi: 10.1007/s10620-018-5452-2
[35]	Shen C, Xuan B, Yan T, et al. m⁶A-dependent glycolysis enhances colorectal cancer progression[J]. Mol Cancer, 2020, 19(1):72. DOI: 10.1186/s12943-020-01190-w. doi: 10.1186/s12943-020-01190-w
[36]	Xiang S, Liang X, Yin S, et al. N⁶-methyladenosine methyltransferase METTL3 promotes colorectal cancer cell proliferation through enhancing MYC expression[J]. Am J Transl Res, 2020, 12(5):1789-1806. pmid: 32509177
[37]	Peng W, Li J, Chen R, et al. Upregulated METTL3 promotes metastasis of colorectal cancer via miR-1246/SPRED2/MAPK signaling pathway[J]. Exp Clin Cancer Res, 2019, 38(1):393. DOI: 10.1186/s13046-019-1408-4.
[38]	Uddin MB, Roy KR, Hosain SB, et al. An N⁶-methyladenosine at the transited codon 273 of p53 pre-mRNA promotes the expression of R273H mutant protein and drug resistance of cancer cells[J]. Biochem Pharmacol, 2019, 160:134-145. DOI: 10.1016/j.bcp.2018.12.014. doi: 10.1016/j.bcp.2018.12.014
[39]	Li T, Hu P S, Zuo Z, et al. METTL3 facilitates tumor progression via an m⁶A-IGF2BP2-dependent mechanism in colorectal carcinoma[J]. Mol Cancer, 2019, 18(1):112. DOI: 10.1186/s12943-019-1038-7. doi: 10.1186/s12943-019-1038-7
[40]	Yang X, Zhang S, He C, et al. METTL14 suppresses proliferation and metastasis of colorectal cancer by down-regulating oncogenic long non-coding RNA XIST[J]. Mol Cancer, 2020, 19(1):46. DOI: 10.1186/s12943-020-1146-4. doi: 10.1186/s12943-020-1146-4
[41]	Ji L, Chen S, Gu L, et al. Exploration of potential roles of m⁶A regulators in colorectal cancer prognosis[J]. Front Oncol, 2020, 10:768. DOI: 10.3389/fonc.2020.00768. doi: 10.3389/fonc.2020.00768
[42]	Meng Y, Li S, Gu D, et al. Genetic variants in m⁶A modification genes are associated with colorectal cancer risk[J]. Carcinogenesis, 2020, 41(1):8-17. DOI: 10.1093/carcin/bgz165.

m⁶A甲基化修饰在消化系统肿瘤中的研究进展

Research advances of m⁶A methylation modification in digestive system neoplasms

RichHTML

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献 42

相关文章 15

编辑推荐

Metrics

本文评价

[1]	胡茹, 李东霖, 严雪冰. 甲基转移酶样蛋白14与肿瘤[J]. 国际肿瘤学杂志, 2022, 49(8): 478-483.
[2]	徐凯, 文刚, 李瑞, 田园. 淋巴细胞与C反应蛋白比值对消化系统肿瘤预后价值的研究进展[J]. 国际肿瘤学杂志, 2022, 49(10): 627-629.
[3]	居欣月, 胡春梅, 赵月, 唐艳. CDX2与胃肠道肿瘤[J]. 国际肿瘤学杂志, 2021, 48(6): 374-376.
[4]	吴汉生, 黄树杰, 庄伟涛, 丁宇, 高枕, 乔贵宾. m⁶A甲基化修饰与肺癌[J]. 国际肿瘤学杂志, 2021, 48(4): 225-230.
[5]	邓波儿, 孔为民. 子宫内膜癌的表观遗传学研究进展[J]. 国际肿瘤学杂志, 2021, 48(3): 184-188.
[6]	曾娟, 杨向红. N⁶-甲基腺嘌呤修饰调节因子与肿瘤[J]. 国际肿瘤学杂志, 2021, 48(2): 96-100.
[7]	何苗, 范奎, 曹芳. 表观遗传与肺癌耐药[J]. 国际肿瘤学杂志, 2021, 48(10): 622-626.
[8]	桑莹冰, 梁俊琴. 皮肤鳞状细胞癌表观遗传学发病机制[J]. 国际肿瘤学杂志, 2020, 47(9): 569-572.
[9]	王坤龙, 张洋, 宿伟鹏, 刘攀, 赵化荣. LSD1和PDPN在舌鳞状细胞癌中的表达及对预后的影响[J]. 国际肿瘤学杂志, 2020, 47(5): 264-271.
[10]	马英骥, 孙丽斌, 邱文生. 长非编码RNA GHET1在消化系统肿瘤中的作用机制[J]. 国际肿瘤学杂志, 2020, 47(5): 304-307.
[11]	朱泽民, 谢智钦, 孙永康, 唐才喜. 微小RNA-223与消化系统肿瘤[J]. 国际肿瘤学杂志, 2020, 47(2): 112-114.
[12]	尹剑云, 王培伟, 顾建伟. m ⁶A甲基化与乳腺癌[J]. 国际肿瘤学杂志, 2020, 47(12): 752-755.
[13]	张千慧, 张洋, 宿伟鹏, 张宋安, 刘攀, 赵化荣. LSD1、MGMT和Ki-67在高级别胶质瘤中的表达及对预后的影响[J]. 国际肿瘤学杂志, 2019, 46(9): 519-525.
[14]	李龙龙，胡孔旺. 赖氨酸去甲基化酶6与肿瘤[J]. 国际肿瘤学杂志, 2019, 46(5): 289-294.
[15]	齐瑞丽, 王华庆. 血管靶向药物联合PD-1/PD-L1抗体在消化系统肿瘤治疗中的研究进展[J]. 国际肿瘤学杂志, 2019, 46(12): 750-754.